Meta Pixel

Ferronova Series A

Australia|Life Sciences

Overview

Surgery remains the only curative treatment for most solid tumour cancer patients, with around 80% of all new cancer patients globally expected to undergo surgery. Yet, despite successful operations, many experience devastating cancer recurrence, often due to microscopic disease left behind.

Ferronova’s mission is to improve surgical precision and patient outcomes so that cancer doesn’t return.

Investment Highlight:

  • Initial focus: Stomach and esophageal cancers - three-year post-surgery survival as low as 27%.
  • Disease burden: The third and sixth leading causes of cancer deaths globally, with 1.8 million new cases each year.
  • Technology: A unique combination of injectable magnetic nanoparticles (FerroTrace®), a companion surgical probe (FerroMag®), and artificial intelligence (AI) to help surgeons identify and remove all cancerous tissue.
  • Clinical validation: 84 patients treated in clinical trials to date across multiple studies.
  • Leadership: Experienced medtech executives with previous company exits to global strategics.
  • Global reach: Clinical collaborations with leading hospitals across the US, Europe and Australia.
  • Strategic investor: Ultragreen.AI (Renew Pharmaceuticals) - providing both capital and global distribution capabilities.
  • Strong backing: Supported by top-tier investors including Uniseed/UniSuper, Artesian Venture Partners, and Ultragreen.ai.

Problem and Solution

Pellentesque tempor a risus in elementum. Proin malesuada mauris et mauris bibendum laoreet.



Vivamus maximus nulla volutpat, ornare lorem a, vulputate enim. In dui nisl, vestibulum eu finibus pretium, eleifend et eros. Vivamus in venenatis risus, ut dictum velit. Praesent rhoncus tempor fermentum. In malesuada tellus eu volutpat posuere. Nullam ut dignissim libero, ut pharetra leo. Nullam sit amet aliquam felis. Suspendisse volutpat ante eget tincidunt feugiat. Nunc placerat sapien et metus molestie, in viverra augue viverra. Donec varius metus ut arcu vestibulum hendrerit. Sed viverra risus neque, ac commodo enim lacinia at.



Morbi posuere tortor vitae sapien faucibus auctor. Donec nulla ipsum, aliquet non bibendum sit amet, viverra non metus. Sed blandit efficitur orci, id dignissim eros.



Donec sollicitudin massa ut tellus gravida, ut luctus lacus maximus. Maecenas porttitor a tellus ac sagittis. Suspendisse potenti. Donec mauris sem, tristique a ipsum vitae, pretium facilisis libero. Nullam interdum mauris in euismod pretium. Class aptent taciti sociosqu ad litora torquent per conubia nostra, per inceptos himenaeos. Nunc felis lectus, ornare a nunc eu, convallis suscipit elit. Donec at magna non orci maximus mollis. Cras commodo venenatis lectus vel fringilla.

Proin mollis, magna consequat placerat tempus, lectus dui porttitor au

Market Opportunity

Proin auctor bibendum ex, non condimentum tortor sodales vitae. Ut feugiat at lorem accumsan consequat.



Suspendisse ac condimentum ipsum, sit amet auctor dui. Aliquam pretium justo in commodo varius.



Pellentesque elementum felis non urna vulputate, non posuere metus suscipit.

Aenean lacinia id quam a lobortis. Cras nibh lorem, vulputate eget purus elementum, pharetra condimentum elit.



Quisque et sagittis ex, vitae ultrices nulla. Vivamus dapibus blandit libero, et scelerisque dui ullamcorper ut. Vivamus ut molestie ex. Integer eget tempus mauris. Quisque volutpat pulvinar urna, posuere pharetra ex auctor vel. Sed id lacus tortor. Proin nisl turpis, tempus a leo in, lacinia volutpat orci.



Aenean nulla nibh, porta a dignissim vitae, laoreet vitae lacus. Nunc in aliquet urna. Vivamus vel turpis a mi consequat venenatis. Pellentesque tincidunt ante

Competitive Advantage

Pellentesque tempor a risus in elementum. Proin malesuada mauris et mauris bibendum laoreet.



Vivamus maximus nulla volutpat, ornare lorem a, vulputate enim. In dui nisl, vestibulum eu finibus pretium, eleifend et eros. Vivamus in venenatis risus, ut dictum velit. Praesent rhoncus tempor fermentum. In malesuada tellus eu volutpat posuere. Nullam ut dignissim libero, ut pharetra leo. Nullam sit amet aliquam felis. Suspendisse volutpat ante eget tincidunt feugiat. Nunc placerat sapien et metus molestie, in viverra augue viverra. Donec varius metus ut arcu vestibulum hendrerit.

Highlights & Milestones

Proin auctor bibendum ex, non condimentum tortor sodales vitae. Ut feugiat at lorem accumsan consequat.



Suspendisse ac condimentum ipsum, sit amet auctor dui. Aliquam pretium justo in commodo varius.



Pellentesque elementum felis non urna vulputate, non posuere metus suscipit.

Aenean lacinia id quam a lobortis. Cras nibh lorem, vulputate eget purus elementum, pharetra condimentum elit.



Quisque et sagittis ex, vitae ultrices nulla. Vivamus dapibus blandit libero, et scelerisque dui ullamcorper ut. Vivamus ut molestie ex. Integer eget tempus mauris. Quisque volutpat pulvinar urna, posuere pharetra ex auctor vel. Sed id lacus tortor. Proin nisl turpis, tempus a leo in, lacinia volutpat orci.



Aenean nulla nibh, porta a dignissim vitae, laoreet vitae lacus. Nunc in aliquet urna. Vivamus vel turpis a mi consequat venenatis. Pellentesque tincidunt ante ut urn

See more exiting opportunities on CapitalHQ

Pictor

Powering diagnostics with protein signatures. Pictor is transforming health with its patented platform providing accessible, affordable, and scalable diagnostic solutions across the human and animal health verticals. PictArray can detect up to 10 diseases or biomarkers from one small serum, milk,...

flag_new zealand
New Zealand NZD
Biotechnology Series B+

ProxyTwin

ProxyTwin™ amplifies expertise. ProxyTwin is a digital twin that works for experts so they can help more people. We create advanced digital replicas of real individuals, enabling them to virtually attend meetings, deliver messages, and hold thousands of interactions simultaneously. Recently...

flag_australia
Australia AUD
Artificial Intelligence Seed Round

HorizonTwo Capital Partners

HorizonTwo Capital Partners is a private equity firm that specialises in advanced manufacturing companies.

flag_australia
Australia AUD
Advanced Manufacturing Private Placement

The Insides Company

First-in-class medtech for intestinal failure. Seeking remaining $1M of a $5M round, on a AUD$17.2M pre-money valuation.

flag_new zealand
New Zealand AUD
Medical Devices Series A

DCARB

We are aiming to raise $CAD5M to fund the ongoing commercialisation of the D100 unit, including working capital to fund the expected growth in sales, and a field trial of the DArc unit. This follows a successful Series B round completed in mid-2023.

flag_australia
Australia CAD
Green Hydrogen Series B+

Grabba Technologies Pty Ltd

Advanced manufacturer of biometric identity authorisation products and electronics supplier to defence industry. We invite expressions of interest for up to $10.0M in growth capital.

flag_australia
Australia AUD
Electronic Equipment & Instruments Private Placement

Join over 45,000+ sophisticated investors

Join Now